CRG and Fundació ACE to collaborate in genomics
The Centre for Genomic Regulation (CRG) (Barcelona, Spain) and the Fundació ACE - Barcelona Alzheimer Treatment & Research Centre (Barcelona, Spain) have signed an agreement to collaborate on scientific projects related to neurodegenerative diseases.
The Centre for Genomic Regulation (CRG) (Barcelona, Spain) and the Fundació ACE - Barcelona Alzheimer Treatment & Research Centre (Barcelona, Spain) have signed an agreement to collaborate on scientific projects related to neurodegenerative diseases.
The agreement, which will initially last for two years, aims to encourage collaboration between the centres. They will work together in the area of genomics as well as functional studies of cases of neurodegenerative diseases.
Dr Mercè Boada, medical director of the ACE Foundation, said, “The start of this collaboration with the CRG represents a huge step forward for our institution and strengthens the basic research of the ACE Foundation. The agreement will allow us to intensify our research on the genetic causes of dementia and complements the collaborations that have been initiated with the international metaconsortia CHARGE and IGAP.”
Xavier Estivill, coordinator of the CRG Genes and Disease programme, commented, “If we study neurodegenerative diseases from a genomic perspective we will probably discover fundamental explanations about the causes. As we age later in life than we did previously, neurodegenerative diseases are becoming more common. Understanding the biological basis of these ailments will help us to delay their appearance, improve diagnosis, and develop new treatments.”
For more information please visit ref="http://www.crg.es">www.crg.es
The Complexity of Oligonucleotide Separations
January 9th 2025Peter Pellegrinelli, Applications Specialist at Advanced Materials Technology (AMT) explains the complexity of oligonucleotide separations due to the unique chemical properties of these molecules. Issues such as varying length, sequence complexity, and hydrophilic-hydrophobic characteristics make efficient separations difficult. Separation scientists are addressing these challenges by modifying mobile phase compositions, using varying ion-pairing reagents, and exploring alternative separation modes like HILIC and ion-exchange chromatography. Due to these complexities, AMT has introduced the HALO® OLIGO column, which offers high-resolution, fast separations through its innovative Fused-Core® technology and high pH stability. Alongside explaining the new column, Peter looks to the future of these separations and what is next to come.
Metabolomics Analysis of Low Birth-Weight Infants Using UHPLC-MS/MS Following Lipid Emulsion
January 10th 2025A recent study aimed to directly compare the changes in serum metabolites among very low birth-rate (VLBW) infants following the administration of the soybean oil-based lipid emulsion and soybean oil, medium-chain triglycerides, olive oil, and fish oil (SMOF) lipid emulsion using untargeted metabolomics techniques.
Analyzing New Drug Modalities: An ISC 2024 Interview with Kelly Zhang
January 10th 2025At ISC 2024 in Liverpool, United Kingdom, LCGC International interviewed Kelly Zhang of Genentech about her work analyzing new drug modalities, such as mRNA, oligonucleotides, peptides, and cell and gene therapies.
